Published in:
Open Access
01-02-2011 | Poster presentation
Safety of drotrecogin alfa (activated) treatment in patients with severe sepsis on renal replacement therapy without additional anticoagulation
Authors:
L Mirea, I Luca Vasiliu, R Ungureanu, A Balanescu, I Grintescu
Published in:
Critical Care
|
Special Issue 1/2011
Login to get access
Excerpt
Patients with sepsis-induced acute renal failure on continuous renal replacement therapy (CRRT), who receive heparin, may be at higher risk of bleeding when drotrecogin alfa activated (DAA) is administered in addition to standard anticoagulation, especially surgical patients. There are some previous observations that no additional anticoagulation is necessary during simultaneous DAA infusion and CRRT. The aim of this study was to evaluate the safety of CRRT during DAA infusion without additional anticoagulant therapy. …